tbuckley/cabot-search huggingface dataset:
Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT).
Authors: Xiaoyu Jia, Darren Richard Feldman, Ilya Glezerman, Lindsay Joy Van Alstine, Dean F. Bajorin, Patricia Fischer, Amanda Hughes, Joel Sheinfeld, Manjit S. Bains, Lilian Reich, George J. Bosl, Robert John Motzer, Sujata Patil
Journal: Journal of Clinical Oncology (2013)

4534 Background: High-dose chemotherapy (HDCT) can achieve durable remissions in 30-60% of GCT patients (pts) requiring salvage treatment. This Phase I/II study investigated safety and efficacy of a novel high-dose regimen (TI-TIC) in this population. Methods: Pts age ≥18 with GCT and progression after ≥1 cisplatin-based regimen were eligible. TI-TIC consists of 1-2 cycles of conventional-dose paclitaxel plus ifosfamide (TI) q14-21 days followed by 3 cycles of high-dose TIC with ASCT q21-28 days. TI dosing was constant. In Phase I, high-dose TIC was administered in 1 of 5 cohorts (I: 6, 8 or 10g/m 2 ; T: 200 or 250mg/m 2 ; C: AUC=21 or 24) using a standard 3+3 dose escalation design to determine the maximal tolerated dose (MTD). In Phase II, Simon’s 2-stage optimal design was used to estimate the complete response (CR) rate at MTD. Results: Of 26 pts (25 male; median age 31; 21 nonseminoma, 5 seminoma) enrolled, 23 received ≥1 cycle of high-dose TIC. Primary sites included testis (n=15), mediastinum (n=6), other (5). In Phase I, 0/18 pts had dose-limiting toxicity (DLT) during TIC cycle 1, making cohort 5 (T 250mg/m 2 , I 10g/m 2 , C AUC=24) the MTD. Toxicities were similar to those reported with TI-CE (Feldman JCO 2010) with little variation across cohorts. However, 2/18 pts in Phase I (1 in cohort 4, 1 in cohort 5) developed grade 3 acute renal insufficiency after cycles 1 and 2 (cycle 3 not given). Both later developed chronic renal insufficiency with 1 pt requiring dialysis 10 months after TI-TIC. A third pt treated in Phase II developed a similar acute and then chronic renal insufficiency pattern with TIC cycles 1 and 2. In Phase II, 7/11 evaluable pts (64%, 90% one-sided CI 40%-100%) achieved a CR, 1 had a partial response with negative markers, and 3 had incomplete responses. Although the CR rate was sufficient to move to the second Simon’s stage, renal toxicity led to premature trial closure. Conclusions: Although there was preliminary evidence of efficacy, high dose TI-TIC was associated with acute and chronic renal insufficiency. TI-CE remains the standard high dose regimen for salvage treatment of GCT at MSKCC. Clinical trial information: NCT00423852.
Hormonal and lifestyle factors as modifiers of risk of breast cancer (BC) in <i>BRCA1</i> and <i>BRCA2</i> carriers (C).
Authors: Asunción Torres, Teresa Ramón y Cajal**, Gemma Llort***, David Fisas**, Carmen Yague***, Consol López**, Maria Teresa León****, Marina Pollán*****
Journal: Journal of Clinical Oncology (2015)

1560 Background: Mutations in the BRCA1/2 genes confer a high lifetime risk of BC. Penetrance varies among populations and individuals suggesting that non-genetic factors may modify the inherited risk. Knowledge of modifiable factors will help to develop preventive strategies. Methods: The study was carried out in 874 women (W) with a BRCA1/BRCA2 germ-line mutation (511 with BC, 51% BRCA2) from 414 families, followed at three Spanish Genetic Counseling Units. Participants gave their consent and the study was approved by the ethics committee. The association between BC, hormonal and lifestyle factors was studied using logistic regression. Huber-White robust estimators of variance were employed to take into account correlations between family members. Age, menopausal status and specific mutated gene were included as co-variables. Results: While late menarche ( ≥ 14 years) was associated with a reduction in BC risk in BRCA1 C (OR:0.48; 95%CI:0.42-0.88, p = 0.016), no similar effect was observed for BRCA2 W (p = 0.252). Moreover, although pregnancy increased BC risk in both BRCA1 and BRCA2 C (OR:2.38; 95%CI:1.26-4.49, p < 0.007; OR:1.89; 95%CI:0.91-3.95, p = 0.09 respectively), a deleterious effect of spontaneous abortion was found only in BRCA1 C (OR:1.66; 95%CI:0.92-3.01, p = 0.09). Furthermore, oral contraceptive (OC) use was also associated with an increased BC risk in the BRCA1 group (OR:1.65; 95%CI:0.98-2.78, p = 0.058). BMI also increased the risk of BC among BRCA1 W (p-trend = 0.014). Finally, breastfeeding, smoking, alcohol intake and exercise did not significantly modify BC risk. Conclusions: Our preliminary data suggest that the hormonal changes associated with pregnancy increases BC risk in mutation C. Obesity and the use of OC also exert a deleterious effect in BRCA1 germline mutation C and could be considered as potential modifiable factors for BC prevention in these group of W.
Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial
Authors: G. Netto, A. Armstrong, D. Wood, P. Creel, A. Partin, A. Jimeno, M. Rudek, D. George, R. Gurganus, M. A. Carducci
Journal: Journal of Clinical Oncology (2009)

5001 Background: Rapamycin is an orally bioavailable and generic mTOR inhibitor with an MTD of 6 mg daily and anticancer activity in solid tumors. We sought to determine the optimal biologic dose (OBD) in the pre-operative setting in men with PC. Methods: We explored the safety and PD activity of 3 and 6 mg of daily oral rapamycin for 14 days prior to radical prostatectomy (RP) in cohorts of 21 men with intermediate risk localized PC. Ten untreated control subjects were included using identical inclusion criteria. Men had Gleason &gt;6 PC involving multiple cores. PD markers in pre-treatment prostate biopsies and RP specimens included p-S6 and p-Akt, 4EBP-1, PTEN, p27, Ki-67, and cleaved caspase-3. Tissue and whole blood sirolimus levels were measured. A Simon 2-stage design using PD efficacy (tumor S6 inhibition &gt; 60%) was utilized. Results: 32 subjects were accrued to this 2 stage pharmacodynamic trial, including 10 control subjects. Median pre-treatment PSA was 6.4 ng/dl, age 60y, Gleason 7 in 85%. 20 accrued to the 3 mg cohort without DLT. However, 2/2 men enrolled at the 6 mg dose level experienced DLT consisting of thrombocytopenia leading to a delay in surgery (&lt;100K) and fever with grade 3 stomatitis. AEs observed in the 3 mg cohort included stomatitis (2), rash (1), post-operative ileus (2), and mild neutropenia (2). One post-operative ileus was observed among control patients. PD studies demonstrated tumor S6 inhibition in &gt;50% of subjects (median 60% decline, p=0.026 vs. baseline) with no negative effect on the state of Akt phosphorylation (p=0.82) or p27 levels (p=0.10). Prostate sirolimus levels (range 7.1–47.2 ng/g) were two-fold higher than whole blood concentrations (range 3.2–19.2 ng/ml). There was no effect of rapamycin on rates of post-operative wound healing or bleeding. PBMC S6 activity inhibition did not correlate with tumor S6 inhibition. Conclusions: The MTD/OBD of daily rapamycin in the pre-operative or prevention setting is 3 mg. This dose demonstrated downstream mTOR inhibition in tumor tissue and achieved adequate prostate tissue levels. Additional PD and genomic studies will be presented. Conducted through the DOD PCCTC and registered at clinicaltrials.gov as NCT00311623 . [Table: see text]
Hepatic artery triplet chemotherapy for liver metastases from colorectal cancer
Authors: F. Levi, R. Adam, P. Innominato, S. Giacchetti, D. Castaing, D. Hauteville, F. Kunstlinger, X. M. Li, D. Machover, M. Bouchahda
Journal: Journal of Clinical Oncology (2007)

14554 Background: Chronomodulated (Chrono) irinotecan (I), 5-fluorouracil (F), leucovorin and oxaliplatin (O) offered sustained tumor control in CRC patients (pts) failing several chemo (Gholam et al. The Oncologist 2006). The relevance of Chrono IFO as hepatic artery infusion (HAI) for long term outcome was investigated in CRC pts with liver metastases. Methods: 32 heavily pretreated non hospitalized CRC pts received 5-day (d) q21 d courses (c) with d1 I (160 mg/m 2 from 2 to 8 am, peak at 5 am) and d2–5 F (600 mg/m 2 /d from 10 pm to 10 am, peak at 4 am) and O (20 mg/m 2 /d from 10 am to 10 pm, peak at 4 pm). Intravenous cetuximab was also given to 3 pts. 172 courses (c) were given (median, 5; 1–15) using a multichannel pump (Mélodie, Aguettant, F). Toxicity was assessed q21 d and response q3 c with CT scan. Results: Prior chemo lines 1/2/3/4+: 3/5/10/14 pts; WHO Performance Status 0/1/2/3: 14/11/6/1 pts; median age: 63 years (32–73); liver only: 25 pts; liver and lung: 7 pts. Treatment was withdrawn for thrombosis (7 pts, 21%) and/or Grade (G) 3 abdominal pain (4 pts ). G3–4 diarrhea occurred in 6 pts (12%). G3–4 leucopenia, anemia and thrombocytopenia were respectively found in 5, 2 and 1 pt. G3 sensory neuropathy occurred in 3 pts with similar G at baseline. 3 pts displayed alopecia. Of 29 pts with measurable lesions, disease progressed in 12 pts (exclusively outside the liver for 4 pts) and was controlled in 17 pts (58%), including 10 objective responses - 34% [95% C.L. 13.4 to 50.6]. Partial hepatectomy was performed in 4 pts with measurable disease (14%): R0 (3 PR) and R1 (1 SD). Median Progression free survival (months, m) is 5 m [1.9 to 8.0] and median survival is 18.4 m [9.9 to 26.9], with 6 pts alive at 2.9 to 63 m. Conclusions: Triplet chronoHAI is safe in heavily pretreated pts and achieves consistent activity against CRC liver metastases despite prior failure on the same 3 drugs. The combination of systemic cetuximab with triplet HAI is feasible and could prevent extra hepatic dissemination, a hypothesis to be soon tested in a prospective European trial. Supported by ARTBC, Hôpital P. Brousse, Villejuif, France. No significant financial relationships to disclose.
NON-INVASIVE CORONARY FLOW RESERVE PREDICTS INCIDENT ATRIAL FIBRILLATION
Authors: Mouaz H. Al-Mallah, Amjad Ahmed, Ihab F. Sulaiman, Mousa Alfaris, Dalia Ahmed, Ahmed Alsaileek, Ahmed Aljizeeri, Abdulbaset Sulaiman
Journal: Journal of the American College of Cardiology (2017)
A CASE OF DEFIBRILLATION THRESHOLD TESTING FAILURE WITH SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR IMPLANTATION IN A HYPERTROPHIC CARDIOMYOPATHY PATIENT
Authors: Sonia Samtani, Hiro Kawata, Govind Rajan, Matthew Dolich, Anjan Batra, Teferi Mitiku
Journal: Journal of the American College of Cardiology (2017)
TRANSACATHETER AORTIC VALVE REPLACEMENT AND MALIGNANCY
Authors: Anat Berkovitch, Victor Guetta, Israel Barbash, Noam Fink, Ehud Regev, Elad Maor, Rafael Kuperstein, Ehud Raanani, Amjad Shalabi, Micha Feinberg, Elad Asher, Amit Segev, Paul Fefer
Journal: Journal of the American College of Cardiology (2017)
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
Authors: Rajendra H. Mehta, Jeffrey D. Leimberger, Sean van Diepen, James Meza, Alice Wang, Rachael Jankowich, Robert W. Harrison, Douglas Hay, Stephen Fremes, Andra Duncan, Edward G. Soltesz, John Luber, Soon Park, Michael Argenziano, Edward Murphy, Randy Marcel, Dimitri Kalavrouziotis, Dave Nagpal, John Bozinovski, Wolfgang Toller, Matthias Heringlake, Shaun G. Goodman, Jerrold H. Levy, Robert A. Harrington, Kevin J. Anstrom, John H. Alexander
Journal: New England Journal of Medicine (2017)

Levosimendan is an inotropic agent that has been shown in small studies to prevent or treat the low cardiac output syndrome after cardiac surgery.In a multicenter, randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of levosimendan in patients with a left ventricular ejection fraction of 35% or less who were undergoing cardiac surgery with the use of cardiopulmonary bypass. Patients were randomly assigned to receive either intravenous levosimendan (at a dose of 0.2 μg per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1 μg per kilogram per minute for 23 hours) or placebo, with the infusion started before surgery. The two primary end points were a four-component composite of death through day 30, renal-replacement therapy through day 30, perioperative myocardial infarction through day 5, or use of a mechanical cardiac assist device through day 5; and a two-component composite of death through day 30 or use of a mechanical cardiac assist device through day 5.A total of 882 patients underwent randomization, 849 of whom received levosimendan or placebo and were included in the modified intention-to-treat population. The four-component primary end point occurred in 105 of 428 patients (24.5%) assigned to receive levosimendan and in 103 of 421 (24.5%) assigned to receive placebo (adjusted odds ratio, 1.00; 99% confidence interval [CI], 0.66 to 1.54; P=0.98). The two-component primary end point occurred in 56 patients (13.1%) assigned to receive levosimendan and in 48 (11.4%) assigned to receive placebo (adjusted odds ratio, 1.18; 96% CI, 0.76 to 1.82; P=0.45). The rate of adverse events did not differ significantly between the two groups.Prophylactic levosimendan did not result in a rate of the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device that was lower than the rate with placebo among patients with a reduced left ventricular ejection fraction who were undergoing cardiac surgery with the use of cardiopulmonary bypass. (Funded by Tenax Therapeutics; LEVO-CTS ClinicalTrials.gov number, NCT02025621 .).
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS &lt; 2).
Authors: Grace K. Dy, Julian R. Molina, Yingwei Qi, Rafat H. Ansari, Sachdev P. Thomas, Helen J. Ross, Jeffrey P Meyers, Araba Adjei, Sumithra J. Mandrekar, Alex A. Adjei
Journal: Journal of Clinical Oncology (2012)

7555 Background: In a retrospective exploratory analysis of E4599, patients (pts) &gt; 70 yo had a higher frequency of and more severe toxicities without apparent survival benefit from the addition of B to C+paclitaxel. We hypothesized that in this pt population, B will have better safety and efficacy profile when used in combination with C+P. Methods: Pts &gt;/= 70 yo with previously untreated stage IIIB/IV (TNM 6 th ed) nonsquamous NSCLC, ECOG PS 0-1, measurable disease and adequate organ function were eligible. C at AUC 6, P at 500 mg/m 2 and B at 15 mg/kg were administered on day 1 of each 21-day cycle for up to 6 cycles followed by maintenance P+B in patients with CR, PR or SD. The primary endpoint was 6-month progression-free survival (PFS) rate. The treatment would be considered promising based on a single arm one-stage binomial design if 34 or more successes out of 55 patients were observed. This design had an exact significance level of 0.05 at 93% power to detect a true success rate of at least 70%. Polymorphisms in VEGFA, FPGS, GGH, SLC19A1 and TYMS in germline DNA were correlated with treatment outcome. Results: 58 eligible pts were enrolled; 29 males/29 females. Median age was 75. Median treatment cycles received was 6. Grade 3 or higher adverse events (AE) were reported in 49 (85%) pts. There were no treatment-related deaths. The most common grade 3/4 AEs(regardless of attribution) were hypertension (10%), fatigue (28%), dehydration (9%), neutropenia (43%) and thrombocytopenia (21%). There were 3 (5%) grade 3/4 hemorrhagic events. 8 (14%) had grade 4 neutropenia and 3 (5%) had grade 4 thrombocytopenia. Grade 3/4 ischemic/thromboembolic events occurred in 6 pts (10%). Thirty-four out of the first 54 (63%, 95% CI: 48.7-75.7%) evaluable pts met the primary endpoint (4 pts were lost to follow-up prior to 6 months). The confirmed ORR was 37.9% (95% CI: 25.5-51.6%). Median time to treatment failure was 4.8 months (95% CI: 3.9-6.4). Median PFS was 7.1 months (95% CI: 5.9-11.7), median OS was 13.7 months (95% CI: 9.4-15.7). Results of SNP analysis will be presented. Conclusions: C+P+B followed by maintenance P+B is an active and tolerable first-line regimen for elderly patients with good PS.
Treatment of Intractable Graft-Versus-Host Disease with Bone Marrow Derived Mesenchymal Stem Cells - A Pilot Clinical Trial.
Authors: Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Miee Seol, Young-Shin Lee, Seong-Gil Ryu, Young-Ah Kang, Kyoo-Hyung Lee
Journal: Blood (2007)
ANTICOAGULATION USE AND INCIDENCE OF CEREBROVASCULAR EVENTS AND MAJOR BLEEDING AFTER CATHETER ABLATION IN PATIENTS WITH PERSISTENT AND LONGSTANDING PERSISTENT ATRIAL FIBRILLATION
Authors: Jackson J. Liang, Melissa A. Elafros, Michael T. Mullen, Daniele Muser, Rajeev K. Pathak, Tatsuya Hayashi, Andres Enriquez, Erica Zado, Pasquale Santangeli, Robert Schaller, Gregory Supple, David Frankel, Fermin Garcia, David Lin, Michael Riley, Saman Nazarian, Sanjay Dixit, Francis Marchlinski, David J. Callans
Journal: Journal of the American College of Cardiology (2017)
FRACTIONAL FLOW RESERVE DERIVED FROM CORONARY COMPUTED TOMOGRAPHY SAFELY REDUCES INVASIVE CORONARY ANGIOGRAPHY RATES AND COST IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Authors: Mark Rabbat, Brian Kauh, Gianluca Pontone, Bjarne Norgaard, John Lopez, Verghese Mathew
Journal: Journal of the American College of Cardiology (2017)
Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab
Authors: Gregory Kaufman, Ronald Witteles, Matthew Wheeler, Patricia Ulloa, Marie Lugtu, Sally Arai, Stanley Schrier, Richard Lafayette, Michaela Liedtke
Journal: Blood (2016)
VEGF-Trap (V-T) overcomes defects in dendritic cell (DC) differentiation without improvement in antigen-specific immune responses
Authors: J. A. Sosman, I. Fricke, N. Mirza, J. Dupont, A. C. Lockhart, A. Jackson, B. LaFleur, D. Gabrilovich
Journal: Journal of Clinical Oncology (2007)

21087 Background: Induction of antitumor immune responses requires adequate DC function. Well-documented DC defects in cancer mediated through tumor-derived vascular endothelial growth factor (VEGF) may lead to tumor escape and limit efficacy of cancer vaccines. V-T with extracellular domains of VEGFR 1/ 2 coupled to Fc IgG1 binds all VEGF-A isoforms. Methods: To determine if inhibition of VEGF signaling improves immune responses, we evaluated 15 cancer pts treated with V-T (2.0–7.0 mg/kg) IV over 1 hr Q 2 wks on a phase I trial. To evaluate immune parameters, PBMC were collected prior to, days 15, 29, and 57 of V-T treatment. Ligand blockade was achieved in all patients. Mature DCs (myeloid and plasmacytoid subsets), and regulatory T cells (T regs) were characterized by expression pattern of CD11c, CD86, CD40, CCR7, CD83, CD123, CD4, CD25, and GITR. T cell function was assessed by allogeneic mixed leukocyte reaction (MLR) and proliferation to tetanus toxoid, influenza, or PHA. Results: V-T treatment did not affect the presence of the total population of DCs, myeloid or plasmacytoid subsets, or myeloid-derived suppressor cells (MDSC). It significantly increased the proportion of mature DCs expressing CD86, CD40, CD83, and CCR7R (p&lt;0.05) without overall improvement in T cell immunity. At 8 wks, 11 pts had either stable disease (SD) or partial response (PR) to the therapy and 4 pts had progressive disease (PD), both with no significant differences in the proportion of MDSC or total DCs. The proportion of mature DCs was significantly increased in pts with SD and PR (p&lt;0.025), but remained unchanged in PD pts. However, functional tests were similar in both groups. Another subset analysis revealed significant improvement in immune responses in 6 pts who had stable or decrease in the MDSC proportion, but not in 9 pts with increases in MDSC. During V-T treatment, Tregs further increased above baseline in pts (p=0.048). Conclusions: These data demonstrate that inhibition of VEGF signaling improves differentiation of DCs in cancer patients, while alone it was not sufficient to improve immune responses. These data illustrates the multifaceted nature of immune deficiency in cancer pts and points to a need for complex approaches to modulation of immune reactivity. No significant financial relationships to disclose.
OPTIMAL METHOD FOR NECROTIC CORE IDENTIFICATION IN CORONARY PLAQUE WITH DUAL-ENERGY COMPUTED TOMOGRAPHY: MATERIAL DECOMPOSITION AND ATOMIC NUMBER
Authors: Hadi Mirhedayati Roudsari, Fay Lin, Bríain Ó. Hartaigh, Asim Rizvi, Ji Hyun Lee, Donghee Han, Mahn Won Park, Yao Lu, Subhi J. Al'Aref, Khalil Anchouche, Ashley Beecy, Kazuyuki Yahagi, Sho Torii, David Fowler, Robert Kutys, James Earls, Jessica Peña, James Min, Renu Virmani
Journal: Journal of the American College of Cardiology (2017)
PREVALENCE AND PREDICTORS OF ATRIAL TACHYARRHYTHMIAS IN ADULT FONTAN PATIENTS
Authors: Anushree Agarwal, Aarthi Sabanayagam, Ahmed Kheiwa, Colin Cunnington, Ian Harris, Edward Gerstenfeld, Charles McCulloch, Elyse Foster, Zian Tseng, Lucas Zier, Petra Jenkins, Jaspal Dua, Devinda Karunaratne, Sahrkaw Muhyaldeen, Amir Zaidi, Adam Fitzpatrick, Clifford Garratt, Bernard Clarke, Andreas Hoschtitzky, Vaikom Mahadevan
Journal: Journal of the American College of Cardiology (2017)
The retention index calculated with dual-phase <sup>18</sup>F-FDG PET/CT in ovarian carcinoma: Determination of the optimal cutoff level using ROC analysis.
Authors: Jin Hwa Hong, Sungeun Kim, Kyung Jin Min, Kyeong A So, Jae Kwan Lee
Journal: Journal of Clinical Oncology (2013)

5539 Background: Although 18 F-fluorodeoxyglucose (FDG) positron emission tomography /computed tomography (PET/CT) is useful as a clinical tool in various malignancies, the maximum standardized uptake value (SUVmax) overlap between malignant and benign lesions is significant. The dual-phase PET/CT has shown its usefulness to differentiate benign from malignant conditions in some solid tumors, but its usefulness has not yet been evaluated in patients with ovarian cancers. Methods: Twenty consecutive patients (thirteen with ovarian cancers and seven with benign lesions) were evaluated preoperatively by dual-phase 18 F-FDG PET/CT (Time of Flight, Philips), performed 1 and 2 hour after injection of 370-555 MBq of 18 F-FDG. The SUVmax at 1 hour (SUVmax1) and at 2 hour (SUVmax2) were determined, and the retention index (RI) was calculated by subtracting the SUVmax1 from the SUVmax2 and dividing by SUVmax1. Results: Area under the receiver operating characteristic (ROC) curve of SUVmax1 and SUVmax2 were 0.753 and 0.835, respectively (95% CI; 0.512, 0.915 versus 0.604, 0.961; p = 0.062 versus 0.001). Area under the ROC curve of RI was 0.901 (95% CI; 0.684, 0.988; p &lt;0.001). When the SUVmax1 cutoff was set to 3.2, the sensitivity and the specificity of the SUVmax1 were 100% and 57.1%, respectively. When the SUVmax2 cutoff was set to 3.9, the sensitivity and the specificity of the SUVmax2 were 100% and 57.1%, respectively. The sensitivity and the specificity of RI were 92.3% and 71.4% when the cutoff was set to 16.67. By pairwise comparisons, the area under the ROC curve of SUVmax2 was significantly higher than that of SUVmax1 (p = 0.032). The area under the ROC curve of the RI was higher than those of SUVmax1 and SUVmax2, but not statistically significant (p = 0.166 and 0.459, respectively). Conclusions: The RI and SUVmax2 are proved to be useful in differentiating ovarian cancers from benign lesions. The use of dual-phase 18 F-FDG PET/CT should be taken into account when the preoperative imaging is ambiguous. Acknowledgements: This study was supported by a grant of the Korean Health Technology R&amp;D Project, Ministry for Health, Welfare &amp; Family Affairs, (A070001) Republic of Korea.